Pharmacological inhibition of STAT3 by BP-1-102 inhibits intracranial aneurysm formation and rupture in mice through modulating inflammatory response
© 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics..
As an inhibitor of STAT3, BP-1-102 can regulate the inflammation response caused by vascular smooth muscle cells (VSMCs) by inhibiting the JAK/STAT3/NF-κB pathway, thereby attenuating the symptoms of intracranial aneurysm (IA). IA mouse model was established by stereotactic injection of elastase to evaluate the effect of BP-1-102. The expression levels of smooth muscle markers and matrix metalloproteinases (MMPs) were detected by qRT-PCR, and the levels of inflammatory factors were detected by ELISA and qRT-PCR. The protein levels of the NF-κB signaling pathway factors were examined by Western blot. BP-1-102 reduced blood pressure in aneurysm mice, up-regulated smooth muscle cell markers MHC, SMA, and SM22, and down-regulated the expression of MMP2 and MMP9 in vascular tissues. At the same time, BP-1-102 also down-regulated the expression levels of inflammatory response factors and the NF-κB pathway proteins. In the IA model, BP-1-102 can reduce the expression of inflammatory factors and MMPs bound to NF-κB by inhibiting the activation of the JAK/STAT3/NF-κB pathway proteins, and then restore the vascular wall elastin to reduce blood pressure, thereby treating aneurysm.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Pharmacology research & perspectives - 9(2021), 1 vom: 14. Feb., Seite e00704 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jiang, Zhixian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.11.2021 Date Revised 30.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/prp2.704 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320371565 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320371565 | ||
| 003 | DE-627 | ||
| 005 | 20240330235558.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/prp2.704 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM320371565 | ||
| 035 | |a (NLM)33474811 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jiang, Zhixian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological inhibition of STAT3 by BP-1-102 inhibits intracranial aneurysm formation and rupture in mice through modulating inflammatory response |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.11.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. | ||
| 520 | |a As an inhibitor of STAT3, BP-1-102 can regulate the inflammation response caused by vascular smooth muscle cells (VSMCs) by inhibiting the JAK/STAT3/NF-κB pathway, thereby attenuating the symptoms of intracranial aneurysm (IA). IA mouse model was established by stereotactic injection of elastase to evaluate the effect of BP-1-102. The expression levels of smooth muscle markers and matrix metalloproteinases (MMPs) were detected by qRT-PCR, and the levels of inflammatory factors were detected by ELISA and qRT-PCR. The protein levels of the NF-κB signaling pathway factors were examined by Western blot. BP-1-102 reduced blood pressure in aneurysm mice, up-regulated smooth muscle cell markers MHC, SMA, and SM22, and down-regulated the expression of MMP2 and MMP9 in vascular tissues. At the same time, BP-1-102 also down-regulated the expression levels of inflammatory response factors and the NF-κB pathway proteins. In the IA model, BP-1-102 can reduce the expression of inflammatory factors and MMPs bound to NF-κB by inhibiting the activation of the JAK/STAT3/NF-κB pathway proteins, and then restore the vascular wall elastin to reduce blood pressure, thereby treating aneurysm | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BP-1-102 | |
| 650 | 4 | |a MMPs | |
| 650 | 4 | |a VSMC | |
| 650 | 4 | |a inflammatory | |
| 650 | 4 | |a intracranial aneurysm | |
| 650 | 7 | |a Aminosalicylic Acids |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a BP-1-102 |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a STAT3 Transcription Factor |2 NLM | |
| 650 | 7 | |a Stat3 protein, mouse |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Jak2 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.24 |2 NLM | |
| 650 | 7 | |a Mmp2 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.4.24.24 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 9 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.35 |2 NLM | |
| 650 | 7 | |a Mmp9 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.4.24.35 |2 NLM | |
| 700 | 1 | |a Huang, Jiaxin |e verfasserin |4 aut | |
| 700 | 1 | |a You, Lingtong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jinning |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Bingyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacology research & perspectives |d 2013 |g 9(2021), 1 vom: 14. Feb., Seite e00704 |w (DE-627)NLM236897691 |x 2052-1707 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:1 |g day:14 |g month:02 |g pages:e00704 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/prp2.704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 1 |b 14 |c 02 |h e00704 | ||